ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor ...

B vitamins sit at the heart of one of the most contested questions in nutritional oncology: whether the very molecules that ...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% ...

Company AnnouncementCOPENHAGEN, Denmark; October 23, 2026Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) ...

The results come as Lilly continues to test Sofe-M in different types of ovarian cancer, with multiple Phase 3 trials now underway.

Do Elevated Blood Test Levels Mean Cancer? / blood cancer, blood-test results, Breast Cancer, cancer, cancer risk, complete ...

The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...

Genmab's Rina-S met Phase 3 endpoints in platinum-resistant ovarian cancer, showing 71% reduced progression risk and 57% ...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC development platform, which is designed to mask the cytotoxic payload carried by the ...

Rupert Lowe, the leader of Restore Britain, has stirred up a furore over folic acid – aka vitamin B9 – being added to our foods. This comes after the UK government announced that, from December, the ...

Ursula A. Matulonis, MD, discussued studies are being conducted assessing the use of mirvetuximab soravtansine in patients with folate receptor-α–positive platinum-resistant ovarian cancer. Ursula A.